Table 1.

Characteristics of Patients With EVALI

Variable	Total (N = 12)
Age, mean ± SD; median; range (minimum-maximum)	30.8 ± 12.1; 27; (18-53)
Sex: Male, No. (%)	8 (67)
Ethnicity, No. (%)
Hispanic	2 (17)
Non-Hispanic	10 (83)
Race: white, No. (%)	12 (100)
Comorbidity, No. (%)	8 (67)
Reported or confirmed tetrahydrocannabinol use, No. (%)	9 (75)
WBC count, mean ± SD, k/uL	15.3 ± 3.5
Absolute lymphocyte count	1.3 ± 0.5
Eosinophils total	0.2 ± 0.5
C-reactive protein, mean ± SD, mg/dL	69.9 ± 93.8
SARS-coV-2 tests, mean ± SD; median; (range minimum maximum)	2.5 ± 1.0; 2; (1-4)
1 Test, No. (%)	1 (8)
2 Tests, No. (%)	7 (58)
3 Tests, No. (%)	2 (17)
4 Tests, No. (%)	2 (17)
SARS-coV-2 test, No. (%)
PCR	30 (97)
Nasopharyngeal	28
BAL	2
IgG antibody	1 (3)
Chest radiographs, No. (%)	12 (100)
Chest CT scan, No. (%)	12 (100)
ICU admission, No. (%)	9 (75)
Ward admission, No. (%)	2 (17)
ED treatment, No. (%)	1 (8)
Hospital length of stay, mean ± SD	6.0 ± 3.7
Bronchoscopy, No. (%)	2 (16.7)
Treatment with corticosteroids, No. (%)	8 (67)
Initial corticosteroid dose in prednisone milligram equivalents, median (interquartile range); (minimum, maximum)	56 (15); (50, 88)
Treatment with antibiotics, No. (%)	12 (100)
Highest oxygen support, No. (%)
Invasive mechanical ventilation	3 (25)
Noninvasive positive pressure ventilation	1 (8)
High-flow nasal cannula	3 (25)
Nasal cannula	5 (42)

EVALI = e-cigarette, or vaping, product use-associated lung injury; PCR = polymerase chain reaction; SARS-coV-2 = severe acute respiratory syndrome coronavirus 2.